Solid dosage forms also have a impervious dif iculties in patients especially for geriatric and paediatric patients.Dysphagia is common among all age groups. Orodispersible formulations (Fast dissolving tablets & Fast dissolving oral thin ilms) constitute an inventive dosage form that overcome the problems swallowing and provides speedy onset of action. The objective of present study was to formulate orodispersible formulations of Hydralazine HCL by different methods (Direct compression method, Sublimation method and solvent casting method). Based on physiochemical evaluations F9 (Direct compression method),SF9 (Sublimation method) for Fast dissolving tablets and H2 formulations (Solvent casting method) for Fast dissolving oral thin ilms were found optimized formula.The optimized formula were kept for stability under long term, accelerated and intermediate conditions for the study period of six months as per ICH guidelines.Based on stability reports the H2 formulations (Fast dissolving oral thin ilms) got a better drug release than Fast dissolving tablets.
INTRODUCTION
A mouth dissolving or disintegrating system can be de ined as a novel dosage form for oral administration, which when placed in mouth, disintegrates rapidly or dissolves in saliva, within a few seconds. A mouth dissolving tablet usually dissolves in oral cavity within 15 seconds to 3 minutes.
Dysphagia, or dif iculty in swallowing, is common among all age groups. Dysphagia is common in about 35% of the general population, as well as an additional 30-40% of elderly patients and 18-22% of all persons in long-term care facilities. This segment of a formulation is specially designed for dysphagia, geriatric, pediatric, bed-ridden, traveling, and psychotic patients who are unable to swallow or refuse to swallow conventional oral formulations.
Mouth dissolving tablets (MDTs) also called orodispersible, orally disintegrating tablets, quickdissolving tablets, fast melt tablets, rapid disintegrating tablets, and freeze-dried wafers. (Lindheimer et al., 2008) Criteria for mouth dissolving tablets 1. Water is not required to swallow and should dissolve or disintegrate in the mouth within a few seconds 2. Have a pleasing mouthfeel 3. Acceptable taste-masking property (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) 4. Be compatible with taste masking and other excipients 5.Allow high drug loading 6.Leave minimal or no residue in mouth after oral administration 7.Have suf icient strength to withstand the rigors of the manufacturing process and post-manufacturing handling 8.Exhibit low sensitivity to environmental conditions such as humidity and temperature 9.Be adaptable and amenable to existing processing and packing machinery 10.Allow the manufacture of tablets using conventional processing and packing equipment at low cost
Advantages of mouth dissolving tablets
1. Ease of administration to patients who cannot swallow, such as the elderly, stroke victims and bedridden patients, patients who should not swallow, such as renal failure patients, and who refuse to swallow, such as pediatrics, geriatrics and psychiatrists patients 2. Patients compliance for disabled, bedridden patients, for traveling and for busy peoples who don't have ready to access to water (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) 3. Good mouthfeel property of mouth dissolving drug delivery system helps to change the basic view of medication drugs 4. The convenience of administration and accurate dosing as compared to liquid formulations 5. The bene it of liquid medication in the form of solid preparation 6. More rapid drug absorption from the pregastric area i.e., mouth, pharynx, and esophagus which may produce rapid onset of action 7. Pre-gastric mucosa can result in improved bioavailability, reduce the dose and improved clinical performance by reducing side effects 8. Improved taste without any residue in mouth after the disintegration 9. The risk of choking or suffocation during oral administration of conventional formulation due to physical obstruction is avoided, thus providing improved safety 10. Bene icial in cases such as heart attack, motion sickness (kinetosis), sudden episodes of allergic attack or coughing, where an ultra-rapid onset of action required Durable and suf icient strength to withstand the rigors of the manufacturing process and handling A fast-dissolving buccal ilm drug delivery system is (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) a ilm containing an active ingredient that fastly dissolves or fastly disintegrates in the saliva, within a few seconds without the need for water or chewing (Irfan et al., 2016) . Fast dissolving ilms for oral administration was a novel approach for patients who experience dif iculties in swallowing tablets or capsules. Geriatric, pediatric, and dysphasia patients associated with many medical conditions face a problem of dif iculty in swallowing solid dosage forms. (Kumar and Bhagyashree, 2013) . One study showed that 26% of 1576 patients experienced dif iculty in swallowing tablets (Arya et al., 2010) . Oral fast-dissolving drug-delivery systems were developed in the late 1970's to overcome the problem of dif iculty in swallowing solid dosage forms (Khatoon et al., 2013) . These systems consist of oral dispersible tablets (ODT) that disintegrate and dissolve quickly in the oral cavity. Oral strips and oral ilms which rapidly dissolve under the tongue or buccal cavity could also improve the dissolution of the poorly soluble drug. It gives the residence time of the dosage form at the site of absorption, hence increase the bioavailability. It gives ease of administration to paediatric, geriatric patients, and also to the patients who are mentally retarded, disabled, or non-cooperative (Madhavi, 2013) . Hydralazine hydrochloride is a medication used to treat high blood pressure and heart fail- (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) ure. This includes high blood pressure in pregnancy. Hydralazine hydrochloride acts as a vasodilator. The drug undergoes extensive irst-passed metabolism with a plasma half-life of 2 -8 h. Hydralazine hydrochloride has a low bio-availability of 50%, and the ef icacy of protein binding is 90 %. 
MATERIALS AND METHODS

The drug Hydralazine
Preparation of Orodispersible tablets by direct compression method
Orodispersible tablets of Hydralazine hydrochloride were prepared by direct compression method (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) using super disintegrants such as crospovidone, croscarmellose sodium, and sodium starch glycolate in varying ratios. All the materials were passed through the mesh number of 60 meshes before mixing for uniformity in particle size. The drug and microcrystalline cellulose were mixed using a glass mortar of pestle in a small portion of both at each time, which blended to get a uniform mixture and kept aside. Then the other ingredients were weighed and mixed in a geometrical order in which the tablets were compressed using an 8mm size punch to get 200 mg weight using ten stations Rimek tablet punching machine (Shukla, 2009 ).
Preparation of Mouth Dissolving Tablet by Subli-mation method
Tablets were prepared by using camphor in different ratios. All the ingredients were passed through #60 mesh separately. Then the ingredients were weighed and mixed in geometrical order, and the tablets were compressed using an 8mm size punch to get 200 mg weight using ten stations Rimek tablet punching machine. The compressed tablets were subjected to sublimation at 60 • C for 1 hour. Compositions of different formulations were prepared by the sublimation technique (Shukla, 2009 ).
Preparation of Buccal Films
Nine batches of drug-loaded buccal ilms were pre- (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) 98.02 ± 0.11 pared using the drug with different polymer (HPMC, pectin, sodium alginate) in different Drug: Polymer ratio (1:1, 1:3, and 1:5). The weighed quantity of polymer was dissolved in the calculated quantity of water and heated on a water bath. The calculated amount of drug was added to the above mixture and stirred well until a homogenous mixture was formed. Then the calculated amount of permeation enhancer and Glycerin were added. The resultant mixture was poured into a Petri dish and air-dried at room temperature for 24 h. The ilms were then peeled off from the Petri dish with the help of a knife and kept in a desiccator (Madhavi, 2013) . Table 2 represented formula for MDTs of Hydralazine Hydrochloride using direct compression method.Based on evaluation parameters F9 formulation was selected as a optimized formula and kept in to stability at different conditions as per ICH guidelines mentioned in Table 1 . (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) Table 3 represented the formula for MDTs of Hydralazine Hydrochloride using sublimation method.Based on evaluation parameters SF9 formulation was selected as a optimized formula and kept in to stability at different conditions as per ICH guidelines mentioned in Table 1 . (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018 ) Table 4 represented the formula for Fast dissolving oral thin ilms of Hydralazine Hydrochloride using solvent casting method.Based on physiochemical evaluations F9,SF9,H2 formulations were selected as a optimized formula and kept in to stability at different conditions as per ICH guidelines (Kumar and Ganapathy, 2018; Muthukumar and Ganapathy, 2018) 
RESULTS AND DISCUSSION
Stability Studies of mouth dissolving tablets F9 & SF9
Stability results represented in Table 5 , Table 6 , Table 8 , Table 9 , Table 10, Table 11, Table 12 , Table 13 , Table 14 , Table 16 , indicated that the optimized formulation F9 and SF9 show better stability under accelerated, intermediate, long term condition as per the ICH guidelines.
Stability studies for orodispersible tablets & Fast dissolving oral thin ilms
Stability is de ined as the time-lapse during which the drug product retains the same property and characteristics that it possessed at the time of manufacture. This process being early development phases.
Instability in the modern formulation is often undetectable only after a considerable storage period under normal conditions. To assess the stability of a formulated product, it is usual to expose it to high-stress conditions to enhance deterioration, and therefore the time required for testing is reduced. Common high stresses are temperature and humidity. This will eliminate unsatisfactory formulation (Mazzo, 1998) .
Strategy of stability testing
1. The study of drug decomposition kinetics 2. The development of stable dosage form 3. Establishment of the expiry date for a commercially available drug product is some of the needs of stability testing 4. Data from which study should be provided on at least 3 primary batches of the drug product 5. The batches should be manufactured to a minimum of a pilot scale.
6. An important point of view of the safety of the patient, patient relieves a uniform dose throughout the shelf life of the product.
Stability Studies of Fast dissolving oral thin ilms (H2)
The stability studies of HPMC [H2] Formulation of the buccal ilm was carried out for 6 months under long term, intermediate, accelerated conditions. The results represented in Table 17, Table 18 , Table 19 , Table 20 . During this period, the formulation was stable and showed no signi icant changes in visual appearance, colour, texture, and drug content.
CONCLUSION
Mouth dissolving tablets
Based on stability results concluded that SF9 gives the results of an effective percentage of drug release of 97.28 ± 0.92 at 12minutes than F9 gives a drug release of 89.42±0.52 at 12 minutes.SF9 is indicating faster and maximum absorption at the site of administration than F9.
Fast dissolving oral thin ilms:
From this study, H2 concluded as an optimized and stable formulation from the results of evaluation & stability studies of Hydralazine Hydrochloride Fast dissolving oral thin ilms by solvent casting method.
Comparative study of mouth dissolving tablets vs. Fast dissolving oral thin ilms 1. Based on stability results concluded that SF9(Mouth dissolving tablets-sublimation method) gives the results of an effective percentage of drug release of 97.28 ± 0.92 at 12minutes (accelerated condition),97.18± 0.92(Long Term Condition),97.24± 0.90(Intermediate condition).
2. Based on stability results concluded that H2(Fast dissolving oral thin ilm-HPMC formulation) gives the results of an effective percentage of drug release of 97.92 ± 0.14 at 60seconds (accelerated condition), 98.68± 0.13 (Long Term Condition),98.02± 0.11(Intermediate condition).
3. Based on the stability results of mouth dissolving tablets (SF9) and Fast dissolving oral thin ilms (H2) formulations compare with the invitro studies, it showed that the Fast dissolving oral thin ilms(H2) got a better drug release than mouth dissolving tablets (SF9).
